Table 4.

Demographic and baseline characteristics

Age (years)	36.61 (13–64)
Male sex (%)	66.67
Duration of illness prior to starting Imatinib (months)	8.4 (0.5–96)
Haemoglobin (g%)	9.85 (6–16)
Total leukocyte counts (cells/mm3)	44,770 (12,550–136,000)
Patients with normal platelet counts (%)	71.95
Patients with thrombocytosis (%)	20.73
Patients with thrombocytopenia (%)	7.32
Patients with basophilia (%)	90.3
Patients with eosinophilia (%)	93.9
Patients with marked splenomegaly (%)	58.54
Patients with moderate splenomegaly (%)	28.05
Patients with spleen tip palpable (%)	7.32
Patients with absent splenomegaly (%)	6.1